123 related articles for article (PubMed ID: 7478430)
1. Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer.
Noberasco C; Bajetta E; Zilembo N; Di Leo A; Cappuzzo F; Bartoli C; Bono A; Bichisao E
Oncology; 1995; 52(6):454-7. PubMed ID: 7478430
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer.
Pérez Carrión R; Alberola Candel V; Calabresi F; Michel RT; Santos R; Delozier T; Goss P; Mauriac L; Feuilhade F; Freue M
Ann Oncol; 1994; 5 Suppl 7():S19-24. PubMed ID: 7873457
[TBL] [Abstract][Full Text] [Related]
3. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK).
Thürlimann B; Castiglione M; Hsu-Schmitz SF; Cavalli F; Bonnefoi H; Fey MF; Morant R; Löhnert T; Goldhirsch A
Eur J Cancer; 1997 Jun; 33(7):1017-24. PubMed ID: 9376181
[TBL] [Abstract][Full Text] [Related]
4. Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.
Wiseman LR; Goa KL
Drugs Aging; 1996 Oct; 9(4):292-306. PubMed ID: 8894526
[TBL] [Abstract][Full Text] [Related]
5. Formestane is feasible and effective in elderly breast cancer patients with comorbidity and disability.
Venturino A; Comandini D; Granetto C; Audisio RA; Castiglione F; Ross R; Repetto L
Breast Cancer Res Treat; 2000 Aug; 62(3):217-22. PubMed ID: 11072786
[TBL] [Abstract][Full Text] [Related]
6. Treatment of advanced breast cancer with formestane.
Murray R; Pitt P
Ann Oncol; 1994; 5 Suppl 7():S11-3. PubMed ID: 7873455
[TBL] [Abstract][Full Text] [Related]
7. Formestane in the treatment of advanced postmenopausal breast cancer.
Possinger K; Jonat W; Höffken K
Ann Oncol; 1994; 5 Suppl 7():S7-10. PubMed ID: 7873464
[TBL] [Abstract][Full Text] [Related]
8. Formestane as treatment of advanced breast cancer in elderly women.
Zilembo N; Buzzoni R; Celio L; Noberasco C; Ferrari L; Laffranchi A; Vicario G; Dolci S; Bajetta E
Tumori; 1994 Dec; 80(6):433-7. PubMed ID: 7900232
[TBL] [Abstract][Full Text] [Related]
9. Formestane: effective therapy in postmenopausal women with advanced breast cancer.
Bajetta E; Zilembo N; Buzzoni R; Noberasco C; Martinetti A; Ferrari L; Bartoli C; Sacchini V; Attili A; Lepera P
Ann Oncol; 1994; 5 Suppl 7():S15-7. PubMed ID: 7873456
[TBL] [Abstract][Full Text] [Related]
10. The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients.
Zilembo N; Bajetta E; Bichisao E; Martinetti A; La Torre I; Bidoli P; Longarini R; Portale T; Seregni E; Bombardieri E
Biomed Pharmacother; 2004 May; 58(4):255-9. PubMed ID: 15183852
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of 4-hydroxyandrostenedione (4-OHA) as first-line treatment in postmenopausal patients with breast cancer after adjuvant therapy.
Bajetta E; Zilembo N; Buzzoni R; Noberasco C; Celio L; Bichisao E
Cancer Treat Rev; 1993 Apr; 19 Suppl B():31-6. PubMed ID: 8481932
[TBL] [Abstract][Full Text] [Related]
12. [Aromatase inhibitors: a review of clinical trials].
Kerbrat P; Lefeuvre C
Bull Cancer; 2000 Dec; 87 Spec No():31-39. PubMed ID: 11250606
[TBL] [Abstract][Full Text] [Related]
13. Advanced breast cancer in elderly patients: which drug after tamoxifen?
Bajetta E
Tumori; 2002; 88(1 Suppl 1):S59-60. PubMed ID: 11989927
[No Abstract] [Full Text] [Related]
14. [Aromatase inhibitors--new possibilities in treatment of breast carcinoma].
Friedrichs K; Jänicke F
Praxis (Bern 1994); 1998 Apr; 87(17):584-8. PubMed ID: 9623325
[TBL] [Abstract][Full Text] [Related]
15. Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study.
Höffken K; Jonat W; Possinger K; Kölbel M; Kunz T; Wagner H; Becher R; Callies R; Friederich P; Willmanns W
J Clin Oncol; 1990 May; 8(5):875-80. PubMed ID: 2185341
[TBL] [Abstract][Full Text] [Related]
16. Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women?
Carlini P; Ferretti G; Di Cosimo S; Colella E; Tonachella R; Romiti A; Tomao S; Frassoldati A; Papaldo P; Fabi A; Ruggeri EM; Cognetti F
J Steroid Biochem Mol Biol; 2003 Jul; 86(1):107-9. PubMed ID: 12943750
[TBL] [Abstract][Full Text] [Related]
17. Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer.
Wiseman LR; McTavish D
Drugs; 1993 Jan; 45(1):66-84. PubMed ID: 7680986
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
McLeskey SW; Zhang L; El-Ashry D; Trock BJ; Lopez CA; Kharbanda S; Tobias CA; Lorant LA; Hannum RS; Dickson RB; Kern FG
Clin Cancer Res; 1998 Mar; 4(3):697-711. PubMed ID: 9533540
[TBL] [Abstract][Full Text] [Related]
19. Proper sequence of endocrine therapies in advanced breast cancer.
Rose C
Acta Oncol; 1996; 35 Suppl 5():44-9. PubMed ID: 9142964
[TBL] [Abstract][Full Text] [Related]
20. Pilot study of formestane in postmenopausal women with breast cancer.
Joseph JK; Lim AK
Med J Malaysia; 1998 Mar; 53(1):37-41. PubMed ID: 10968135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
